Praxis Precision Medicines

brain amyloid alzheimers strings detailed web complicated thought
Biotech

Praxis epilepsy drug reduces seizures in phase 2 trial

Participants who received relutrigine saw an average 46% reduction in their seizures during the double-blind part of the study.
James Waldron Sep 3, 2024 10:21am
graphic of the brain and the electrical signals that make it up

Praxis' epilepsy drug hits in phase 2, sparking stock rise

Mar 26, 2024 10:24am
stock market down crash fail shares

Praxis share price halved by tremor fail but still plans phase 3

Mar 3, 2023 9:05am
graphic of the brain and the electrical signals that make it up

Praxis ends year on high with $100M biobucks UCB deal

Dec 14, 2022 5:29am
Praxis CEO Marcio Souza

Praxis acts fast as depression drug flunks late-phase test

Jun 6, 2022 9:40am
FDA

FDA slaps clinical hold on Praxis’ leading epilepsy candidate

Apr 29, 2022 12:31pm